Week 32 - Aug 4-10, 2025

🚀 Biotech & Pharma Industry Updates 🚀Here’s a roundup of some of the most notable developments in neuroscience, oncology, mental health, and beyond:🔹 Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel PET Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients — Breakthrough imaging tracer could change how we track MS progression.🔹 PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License — Advancing PTSD treatment with MDMA-assisted psychotherapy.🔹 Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies — Exploring blockchain assets to fund next-generation cancer therapies.🔹 RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications? — A controversial move raising concerns over pandemic preparedness and research.🔹 Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference — New insights on myeloma diagnostics from an industry innovator.🔹 Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) — Promising early data for a first-in-class neuroprotective MS drug.🔹 Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing — Major litigation with potential market-wide implications.💡 Follow the BioTech Weekly newsletter for more updates on biotech breakthroughs, regulatory milestones, and investment trends in life sciences.#Biotech #Pharma #Neuroscience #Oncology #MentalHealth #MS #DrugDevelopment #Innovation #BioTechWeekly #PodcastDisclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.

There are no comments yet.

Please log in to write the first comment.